Filing Flows › Bristol Myers Squibb (BMY) › Guidance history
Bristol Myers Squibb (BMY) guidance history: what it guided and what it reported
Bristol Myers Squibb gave guidance in 12 earnings releases on file since Feb 2, 2024. Of 2 guided periods since reported, it met or beat its own guidance once (50%). Revenue: 1 of 1, on average +0.9% against the guided midpoint. Its releases raised guidance 7 times and lowered it once.
Revenue
Met or beat 1 of 1 periods (1 above, 0 within, 0 below).
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $46.0B–$47.5B (Feb 5, 2026) → reaffirmed $46.0B–$47.5B (Apr 30, 2026) → raised $49.0B–$50.0B (Jul 30, 2026) → raised $49.8B–$50.2B (Oct 29, 2026) | — | to be reported | — |
| FY2025 | $45.5B (Feb 6, 2025) → raised $45.8B–$46.8B (Apr 24, 2025) → raised $46.5B–$47.5B (Jul 31, 2025) → raised $47.5B–$48.0B (Oct 30, 2025) | $48.2B | above the range | +0.9% |
Gross margin
This line is not in the statements Filing Flows reads, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | 69.0%–70.0% (Feb 5, 2026) → reaffirmed 69.0%–70.0% (Apr 30, 2026) → reaffirmed 69.0%–70.0% (Jul 30, 2026) → reaffirmed 69.0%–70.0% (Oct 29, 2026) | — | to be reported | — |
| FY2025 | 72.0% (Feb 6, 2025) | — | — | — |
Adjusted gross margin
The guide is on an adjusted basis that the GAAP statements do not show, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2024 | 74.0% (Feb 2, 2024) | — | — | — |
Operating expenses
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $16.5B (Jul 30, 2026) | — | to be reported | — |
Tax rate
Met or beat 0 of 1 periods (1 above, 0 within, 0 below).
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | 18.0% (Feb 5, 2026) → reaffirmed 18.0% (Apr 30, 2026) → reaffirmed 18.0% (Jul 30, 2026) → reaffirmed 18.0% (Oct 29, 2026) | — | to be reported | — |
| FY2025 | 18.0% (Feb 6, 2025) | 24.4% | above the range | +6.4 pts |
| FY2024 | 17.5% (Feb 2, 2024) | — | — | — |
Other income
This line is not in the statements Filing Flows reads, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | −$700M (Feb 5, 2026) → reaffirmed −$700M (Apr 30, 2026) → reaffirmed −$700M (Jul 30, 2026) → reaffirmed −$700M (Oct 29, 2026) | — | to be reported | — |
| FY2025 | $30.0M (Feb 6, 2025) → raised $100M (Apr 24, 2025) → raised $250M (Jul 31, 2025) → raised $500M (Oct 30, 2025) | — | — | — |
| FY2024 | $250M (Feb 2, 2024) | — | — | — |
The latest quarter
Bristol Myers Squibb, Q3 2026: revenue $13.1B (+7% year over year), operating margin 19.4%, net earnings $2.2B, operating cash flow $4.2B. The chart follows the revenue to costs, profit and cash.
Questions
Does Bristol Myers Squibb beat its guidance?
Bristol Myers Squibb gave guidance in 12 earnings releases on file since Feb 2, 2024. Of 2 guided periods since reported, it met or beat its own guidance once (50%). Revenue: 1 of 1, on average +0.9% against the guided midpoint.
How often does Bristol Myers Squibb raise guidance?
Its earnings releases raised guidance 7 times and lowered it once since Feb 2, 2024.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.